Drug intelligence / Profile preview

Liangxue ointment

Development stage: Unknown
Lead developer: Athenex
Administration: Topical

Overview

Liangxue ointment is a Traditional Chinese Medicine (TCM) topical formulation developed for the management of hand-foot syndrome (HFS), a common dermatological toxicity associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs). The formulation is based on the TCM principle of "cooling the blood" (Liangxue) to address the heat and toxins believed to cause the erythema, pain, and skin peeling characteristic of HFS. It is currently being evaluated in clinical trials, such as NCT06583369, as a potential alternative or adjunct to standard treatments like urea cream to improve patient quality of life and maintain adherence to primary cancer therapies.

Brand names: Liangxue ointment
Other names: Liangxue GaoCooling Blood Ointment

Beyond the preview

Go deeper on Liangxue ointment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liangxue ointment.

Explore the full profile